Studies have demonstrated that TERTp mutation predicts a favorable prognosis in the IDH‐mt glioma subgroup while indicating a poor prognosis in the IDH‐wt subgroup [13, 15, 16]. The gene discussed is IDH2; the disease is central nervous system cancer.